Cerebral infarction is ischemic necrosis or softening of limited brain tissue due to impaired blood circulation, ischemia and hypoxia in the brain. Drug treatment for cerebral infarction should be tailored to different periods and different etiologies by selecting the appropriate drugs. Anti-platelet aggregation drugs are the basic drugs for the treatment of cerebral infarction, mainly including aspirin, clopidogrel, cilostazol, etc. These drugs inhibit platelet aggregation and release so that the local thrombus no longer progresses and expands. When taking such drugs, attention should be paid to the risk of bleeding, and timely consultation should be made to adjust the medication if gum bleeding or black stool occurs. Statin use is also very important for non-cardiogenic atherosclerotic cerebral infarction. Commonly used are atorvastatin and rasulvastatin. Those with hypertension should control their blood pressure and take oral antihypertensive drugs. Antiplatelet agents, statins, and antihypertensive drugs are the three cornerstones of cerebral infarction treatment. For cerebral infarction caused by atrial fibrillation, anticoagulants are often applied to prevent re-embolization. The commonly used oral anticoagulant is warfarin, which requires INR monitoring (controlled at 2.0-3.0), while some newer oral anticoagulants, such as dabigatran, do not require INR monitoring. in addition, common heparin intravenous pumping and low molecular heparin subcutaneous injection are commonly used in the acute phase. As patients with cerebral infarction are often accompanied by high-risk factors such as diabetes mellitus and hyperhomocysteinemia, these risk factors should be controlled at the same time, and the corresponding hypoglycemic drugs should be applied under the guidance of doctors, and the combination of folic acid, vitamin B6 and vitamin B12 should be chosen to lower homocysteine. In addition, some traditional Chinese medicines, such as circulation improvement and neurotropic drugs, can also play an auxiliary therapeutic role. In conclusion, drugs are only one aspect of the treatment of cerebral infarction. Individualized treatment plans should be selected for the etiology and the risk factors of cerebrovascular disease present in patients, and comprehensive treatment should be provided under the guidance of doctors and regular review.